Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous
system. The inflammation is driven significantly by autoreactive lymphocytes, which recruit …

Nucleoside-based drugs, recognized as purine or pyrimidine analogs, have been potent
therapeutic agents since their introduction in 1950, deployed widely in the treatment of …

Gemcitabine is a nucleoside analog that has been successfully used in the treatment of
multiple cancers. However, intrinsic or acquired resistance reduces the chemotherapeutic …

Background Acute myeloid leukemia (AML) remains a devastating disease with a 5-year
survival rate of less than 30%. AML treatment has undergone significant changes in recent …

The lack of targeted therapies for triple-negative breast cancer (TNBC) contributes to their
high mortality rates and high risk of relapse compared to other subtypes of breast cancer …

Acute myeloid leukemia (AML) patients display dismal prognosis due to high prevalence of
refractory and relapsed disease resulting from chemoresistance. Treatment protocols …

Before the contemporary development of rationally designed antineoplastic therapies,
cladribine was identified as a lymphocyte-specific agent. Its profound impact on the natural …

Originally studied in lymphoid diseases, cladribine (CdA) is an adenosine deaminase
resistant analog of adenosine that was later discovered to induce myeloid cell apoptosis …

Many drugs require extensive metabolism en route to their targets. High-resolution
visualization of prodrug metabolism should therefore utilize analogs containing a small …

Cladribine was synthesized as a purine analogue drug that inhibited adenosine deaminase.
It received FDA approval in the 1980s for treatment of hairy cell leukemia. Given its toxicity …